Canaccord Genuity Group Forecasts Strong Price Appreciation for Guardant Health (NASDAQ:GH) Stock

Guardant Health (NASDAQ:GH) had its price objective increased by investment analysts at Canaccord Genuity Group from $125.00 to $135.00 in a research note issued on Friday, Marketbeat reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target suggests a potential upside of 30.94% from the stock’s current price.

A number of other research firms have also issued reports on GH. Citigroup lifted their target price on Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Friday. Wells Fargo & Company raised their price objective on shares of Guardant Health from $93.00 to $120.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. JPMorgan Chase & Co. boosted their target price on shares of Guardant Health from $90.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Barclays restated an “overweight” rating and set a $130.00 target price on shares of Guardant Health in a report on Friday. Finally, Stifel Nicolaus lifted their price target on shares of Guardant Health from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Twenty-one equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $117.43.

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $103.10 on Friday. The stock has a market cap of $12.99 billion, a price-to-earnings ratio of -31.15 and a beta of 1.63. Guardant Health has a 12 month low of $34.88 and a 12 month high of $120.74. The stock’s 50 day moving average price is $106.69 and its 200 day moving average price is $86.22.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The business had revenue of $281.27 million during the quarter, compared to analysts’ expectations of $269.74 million. During the same period in the prior year, the firm posted ($0.62) earnings per share. The business’s quarterly revenue was up 39.4% compared to the same quarter last year. On average, sell-side analysts expect that Guardant Health will post -2.9 EPS for the current year.

Insider Activity

In other news, CEO Amirali Talasaz sold 100,000 shares of the stock in a transaction on Monday, December 8th. The stock was sold at an average price of $105.05, for a total value of $10,505,000.00. Following the completion of the sale, the chief executive officer owned 168,223 shares in the company, valued at $17,671,826.15. This represents a 37.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Chris Freeman sold 31,452 shares of the firm’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $103.07, for a total value of $3,241,757.64. Following the completion of the sale, the insider directly owned 25,987 shares of the company’s stock, valued at approximately $2,678,480.09. This trade represents a 54.76% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 434,511 shares of company stock worth $45,580,887. 6.10% of the stock is owned by corporate insiders.

Institutional Trading of Guardant Health

Several hedge funds and other institutional investors have recently modified their holdings of the company. V Square Quantitative Management LLC acquired a new stake in Guardant Health during the fourth quarter valued at $27,000. Chesapeake Asset Management LLC purchased a new stake in shares of Guardant Health during the 4th quarter worth about $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Guardant Health during the 4th quarter valued at about $31,000. Elyxium Wealth LLC bought a new stake in shares of Guardant Health in the 4th quarter valued at approximately $35,000. Finally, Parallel Advisors LLC increased its holdings in Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after buying an additional 219 shares during the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Key Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.